Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: May antinucleosome antibodies be predictive?;L'evoluzione da sindrome da anticorpi antifosfolipidi primaria a lupus eritematoso sistemico: Possono gli anticorpi anti-nucleosomi essere predittivi?

Reumatismo

Volumn 60, Issue 3, 2008, Pages 185-191

  Andreoli, Laura ^a   Pregnolato, F ^b   Burlingame, R W ^c   Fanelli, V ^b   Allegri, F ^a   Radice, A ^d   Corace, C ^d   Sinico, R A ^d   Tincani, A ^a   Meroni, P L ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c INOVA DIAGNOSTICS INC   (United States)

^d SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

Antichromatin antibodies; Antinucleosome antibodies; Primary antiphospholipid syndrome; Systemic lupus erythematosus

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NUCLEOSOME ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNITY; CHROMATIN; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIGENS; DISEASE PROGRESSION; DNA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; NUCLEOSOMES; PROGNOSIS;

EID: 57149134119     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hughes G. The anticardiolipin syndrome. Clin Exp Rheumatol 1985; 25: 285-6.
2. Alarcón-Segovia D, Sánchez-Guerrero J. Primary anti-phospholipid syndrome. J Rheumatol 1989; 16: 482-8.
3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-34.
4. Piette JC, Wechsler B, Frances C, Papo T, Godeau P. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 1993; 20: 1802-3.
5. Seisedos L, Mu oz-Rodríguez J, Cervera R, Font J, Ingelmo M. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. Lupus 1997; 6: 285-6.
6. Gomez-Puerta JA, Martin H, Amigo MC, Aguirre MA, Camps MT, Cuadrado MJ, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 2005; 84: 225-30.
7. Tarr T, Lakos G, Bhattoa HP, Szegedi G, Shoenfeld Y, Kiss E. Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus. Lupus 2007; 16: 324-8.
8. Shoenfeld Y. APS-More systemic disease than SLE. Clin Rev Allergy Immunol 2007; 32: 129-30.
9. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Vilpando CG, et al. Complement C3 activation is required for anti-phospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211-20.
10. Fischetti F, Durigotto P, Pellis V, Debeus A, Macor P, Bulla R, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106: 2340-6.
11. Asherson RA, Piette JC, Cervera R. "Primary", "Secondary", "Seronegative", "Catastrophic" and other subsets of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette J-C, Shoenfeld Y eds. The anti-phospholipid syndrome II: Autoimmune thrombosis. Elsevier Science 2002: 285-96.
12. Amoura Z, Chabre H, Koutouzov S, Lotton C, Cabrespines A, Bach J-F, Jacob L. Nucleosome restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 1994; 37: 1684-8.
13. Burlingame RW, Rubin RL, Balderas RS, Theofilopoulos AN. Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest 1993; 91: 1687-96.
14. Burlingame RW. Recent advances in understanding the clinical utility and underlying cause of antinucleosome (antichromatin) autoantibodies. Clinical and Applied Immunology Reviews 2004; 4: 351-66.
15. Simón JA, Rojas-Serrano J, Cabiedes J, Alcocer-Varela J. Antinucleosome antibodies may help predict development of systemic lupus erythematosus in patients with primary antiphospholipid syndrome. Lupus 2004; 13: 177-81.
16. Andreoli L, Pregnolato F, Burlingame RW, Allegri F, Rizzini S, Fanelli V, et al. Antinucleosome antibodies in primary antiphospholipid syndrome: A hint at systemic autoimmunity? J Autoimmun 2008; 30: 51-7.
17. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
18. Tincani A, Allegri F, Sanmarco M, Cinquini M, Taglietti M, Balestrieri G, et al. Anticardiolipin antibody assay: a metodological analysis for a better consensus in routine determination-an operative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575-83.
19. 2glycoprotein I antibodies. A marker of antiphospholipid syndrome? Lupus 1995; 4: 122-30.
20. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74: 1597-603.
21. Pincus T, Schur PH, Rose JA, Decker JL, Talal N. Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Eng J Med 1969; 281: 701-5.
22. Bernstein RM, Bunn CC, Hughes GRV. Identification of autoantibodies to acid antigens by counterimmuno-electrophoresis. Ann Rheum Dis 1982; 41: 554-5.
23. Meroni PL, Ronda N, De Angelis V, Grossi C, Raschi E, Borghi MO. Role of anti-beta2 glycoprotein I antibodies in antiphospholipid sindrome: in vitro and in vivo studies. Clin Rev Allergy Immunol 2007; 32: 67-74.
24. Salmon JE and Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol 2008; 77: 51-6.
25. Cervera R, Viňas O, Ramos-Casals M, Font J, Garcia-Carrasco M, Siso A, et al. Antichromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 2003; 62: 431-4.
26. Amoura Z, Koutouzov A, Chabre H, Cacoub P, Amoura I, Musset L, et al. Presence of antinucleosome antibodies in a restricted set of connective tissue diseases. Arthritis Rheum 2000; 43: 76-84.
27. Manfredi AA, Rovere P, Galati G, Heltai S, Bozzolo E, Soldini L, et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by Antiphospholipid Antibodies. Arthritis Rheum 1998; 41: 205-14.
28. Manfredi AA, Rovere P, Heltai S, Galati G, Nebbia G, Tincani A, et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum 1998; 41: 215-23.
29. Pascual V, Farkas L and Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006; 18: 676-82.